

CURATIX

THERAPIES FOR RADICAL CURE



Choukri Ben Mamoun, PhD
Founder



Joseph Gennaro, PhD
CTO



Jae-Yeon Choi, PhD
Scientific Director



Rose Wang, MBA
Consultant



Elijah Paintsil, MD

Professor of Pediatrics &
Section Chief, Yale



James Boyle, PhD

Executive Director of
Venture Development, Yale



Chris VanderWaal

Professor and Chair of
Chemistry, UC-Irvine



John Puziss, PhD

Executive Director of
Business Development, Yale



Develop more effective and safer anti-microbial therapies and advanced diagnostics



Antimicrobial Resistance: An Urgent Threat

1.27M

**2019 deaths directly
attributable to AMR**

10M


**Annual deaths by
2050 if no action
taken**

\$13.5B

**Amount spent
annually to combat
AMR**

Candida auris


“Urgent threat” CDC, March 2023
1-4% of cases resistant to all clinical antifungals




Increasing incidence
Ineffective treatments
Poor diagnostics

Babesiosis



“Emerging threat” CDC, March 2023
~90% cases undiagnosed




Potentiators of Anti-Microbial Susceptibility



Rapid Diagnostic Testing (RDT)



Anti-microbial adjuvants




Detect infection before symptoms



Therapeutics

\$4M in cumulative non-dilutive funding by 2024

Protected by Yale IP



Due diligence

Merit-based funding

De-risk

Spin out

Diagnostics

In negotiations for \$2M of funding
Protected by Yale IP



Radical cure for the ID pipeline



Thank you!

info@curatixbio.com

